"The pharmaceutical industry is facing a continued decline in the productivity of new drug approvals—especially evident in new molecules designed to modulate "unprecedented" targets. Participants in this panel will discuss the factors contributing to clinical stage attrition and how companies are re-engineering
drug discovery with new approaches such as predictive human biology. The panel will cover how such efforts increase the efficiency, productivity and cost-effectiveness of drug discovery, as well as discuss the potential for increasing success rates in the clinical stages of drug development."

Objective1: Convince the audience that clinical-stage attrition is the single most important issue facing the pharmaceutical industry today.

Objective2: Provide a compelling rationale for bringing complex biology back into the discovery paradigm.

Objective3: Describe how high-throughput biology can be used to screen for, identify and select the best compounds.